Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
27
datasets available to search
ShareScore release 0.9.0
Dataset results
27 results for “radiopharmaceuticals”
Figure 3 in Cytotoxicity of iodine-131 radiopharmaceutical in tumor and non-tumor human cells and radioprotection by integral juices of Vitis labrusca L.
Figure 3. Mean absorbance and standard deviation of MRC-5 cells treated with conventional and organic grape juices, exposed or not to UV-C irradiation (10 and 20 µL/mL), treated alone or in cytoprotective tests with I-131 (1.85 MBq/mL). CO: Control; 1x104 cells per well, incubated for 24 and 48 hours, n = 3, Tukey test.*Statistically significant result compared to Control;# Statistically significant result compared to treatment with I-131; & Statistically significant result compared to treatment with the same juice concentration, without I-131.
Figure 2 in Cytotoxicity of iodine-131 radiopharmaceutical in tumor and non-tumor human cells and radioprotection by integral juices of Vitis labrusca L.
Figure 2. Mean absorbance and standard deviation of HepG2/C3A cells treated with conventional and organic grape juices, exposed or not to UV-C irradiation (10 and 20 µL/mL), treated alone or in cytoprotective tests with I-131 (1.85 MBq/mL). CO: Control; 1x104 cells per well, incubated for 24 and 48 hours, n = 3, Tukey test. *Statistically significant result compared to Control; #Statistically significant result compared to treatment with I-131; &Statistically significant result compared to treatment with the same juice concentration, without I-131.
Figure 1 in Cytotoxicity of iodine-131 radiopharmaceutical in tumor and non-tumor human cells and radioprotection by integral juices of Vitis labrusca L.
Figure 1. Mean absorbance and standard deviation of HepG2/ C3A (A) and MRC-5 (B) cells treated with I-131. CO: Control; 1x104 cells per well, incubated for 24 and 48 hours, n = 3. *Statistically significant result compared to Control (p <0.05, Dunnett's test).
New leads for fragment based design of Re/Tc radiopharmaceutical agents: Raw Diffraction Images
<p>Multiple coordination possibilities of <em>fac</em>-[Re(CO)<sub>3</sub>]<sup>+</sup> to a protein, were found bound to the Asp, Glu, Arg and His amino acid residues as well as to the C-terminal carboxylate in the vicinity of Leu and Pro and are described in the publication titled " <em>New leads for fragment based design of Re/Tc radiopharmaceutical agents</em>" written by Brink & Helliwell, <em>IUCrJ</em>, 2017</p> <p>The raw diffraction images for the DLS and Cu Kalpha data sets are made available at the Zenodo research data archive, as specified in the publication.</p>
Radiopharmaceuticals Analysis for Detailed Insights And INternational Tracking of Safety
ClinicalTrials.gov study NCT06483685. IPD Sharing: NO. Countries: 1. Publications: 3.
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
ClinicalTrials.gov study NCT04831307. IPD Sharing: Not stated. Countries: 1. Publications: 0.
[18F]-F13640 as a New Brain Radiopharmaceutical
ClinicalTrials.gov study NCT03347331. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
ClinicalTrials.gov study NCT04535349. IPD Sharing: NO. Countries: 1. Publications: 1.
Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)
ClinicalTrials.gov study NCT01128023. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
ClinicalTrials.gov study NCT00316797. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ClinicalTrials.gov study NCT03030885. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiopharmaceutical Treatment of Advanced Kidney Cancer
ClinicalTrials.gov study NCT06783348. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Development of a new class of radiopharmaceuticals for diagnosis and therapy of CXCR4-expressing malignancies based on the endogenous CXCR4 antagonist EPI-X4
<p>The pathological overexpression of the C-X-C motif chemokine receptor 4 (CXCR4) in more than 23 human cancers designate CXCR4 as a “wide spectrum” molecular target in oncology. In nuclear medicine, radiolabeled molecules can specifically target such cell surface receptors and can be designed for blending diagnostic and therapeutic properties within the same molecule (radio-theranostics). Recently, the applicants have identified an endogenous antagonist of CXCR4, termed EPI-X 4. EPI-X4 is a 16-mer peptide derived from human serum albumin that specifically binds CXCR4 but no other G-protein coupled receptors, without causing receptor activation. Several synthetic derivatives of EPI-X4 with increased affinity for CXCR4, resistance against proteolytic degradation in blood and high systemic retention times have been developed. Radiotheranostics based on EPI-X4 may thus offer new imaging tests and therapeutic options to patients suffering from CXCR4-expressing malignancies. The proposed research project would be the first study aiming to evaluate a new class of radiopharmaceuticals based on an endogenous peptide naturally present in the human body, which may have less off-target effects as compared to small molecules.</p>
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
ClinicalTrials.gov study NCT03125629. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers
ClinicalTrials.gov study NCT01558362. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Half-Dose Radiopharmaceutical in Wide Beam Reconstruction
ClinicalTrials.gov study NCT01499654. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Supplemental Data Files for Advances in Organ-Specific Dosimetry Models for Radionuclides and Radiopharmaceuticals at Their Macro And Micro Scales
<p>Data sets for Aims 1 and 2 of my dissertation. Both aims contain three excel spreadsheets for a total of 6 files with the computed specific absorbed fractions and S-values.</p>
Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer
ClinicalTrials.gov study NCT03207139. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Preparation of Radiopharmaceuticals by Automaton: Operators Dosimetry
ClinicalTrials.gov study NCT03974256. IPD Sharing: NO. Countries: 1. Publications: 0.
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
ClinicalTrials.gov study NCT06943495. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.